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The appropriate use of systemic antifungals is vital in the prevention and treatment of invasive fungal infection (IFI) in immu-
nosuppressed children and neonates. This multicenter observational study describes the inpatient prescribing practice of anti-
fungal drugs for children and neonates and identifies factors associated with prescribing variability. A single-day point preva-
lence study of antimicrobial use in hospitalized neonates and children was performed between October and December 2012. The
data were entered through a study-specificWeb-based portal using a standardized data entry protocol. Data were recorded from
17,693 patients from 226 centers. A total of 136 centers recorded data from 1,092 children and 380 neonates receiving at least one
antifungal agent. The most frequently prescribed systemic antifungals were fluconazole (n 355) and amphotericin B deoxy-
cholate (n 195). The most common indications for antifungal administration in children were medical prophylaxis (n 325),
empirical treatment of febrile neutropenia (n 122), and treatment of confirmed or suspected IFI (n 100 [14%]). The treat-
ment of suspected IFI in low-birthweight neonates accounted for the majority of prescriptions in the neonatal units (n 103).
An analysis of variance (ANOVA) demonstrated no significant effect of clinical indication (prophylaxis or treatment of systemic
or localized infection) on the total daily dose (TDD). Fewer than one-half of the patients (n 371) received a TDDwithin the
dosing range recommended in the current guidelines. Subtherapeutic doses were prescribed in 416 cases (47%). The predomi-
nance of fluconazole and high incidence of subtherapeutic doses in participating hospitals may contribute to suboptimal clinical
outcomes and an increased predominance of resistant pathogenic fungi. A global consensus on antifungal dosing and coordi-
nated stewardship programs are needed to promote the consistent and appropriate use of antifungal drugs in neonates and
children.
Antimicrobial agents are among the most commonly pre-scribed drugs in neonates and children. The widespread use
of broad-spectrum antimicrobials is known to contribute to anti-
microbial resistance, while the failure to initiate appropriate treat-
ment is associated with significantly increased attributable mor-
tality (1). The appropriate use of antifungals is of particular
importance in the prevention and treatment of infection in the
presence of severe intercurrent illness, prematurity, and immuno-
suppression. Invasive fungal infections (IFI) continue to be asso-
ciatedwith anunacceptably highmortality rate in these vulnerable
populations. In low- and extremely low-birthweight neonates, IFI
is associated with an attributable mortality rate of 30 to 40% (2).
In the setting of hematopoietic stem cell transplantation (HSCT),
the attributable mortality rates from IFI are 30 to 40% for yeast
infections and up to 70% for mold infections (3, 4).
The surveillance of antimicrobial use in hospitals is an impor-
tant means of observing prescribing trends, linking results with
antimicrobial resistance patterns, and identifying areas for im-
provement in safe and effective prescribing. Cross-sectional point
prevalence surveys (PPS) have provided informative data on the
patterns of antimicrobial prescribing in adults and,more recently,
in children (5, 6). To our knowledge, PPS methodologies have
until now not been used to describe antifungal use in children and
neonates. Here, we present data on antifungal prescribing from
the Antibiotic Resistance and Prescribing in European Children
(ARPEC) study, a multicenter global observational study investi-
gating the current variation in antimicrobial prescription prac-
tices in hospitals.
MATERIALS AND METHODS
A single-day point prevalence study (PPS) of antimicrobial use was car-
ried out in 226 centers. The details of the ARPEC study design have been
outlined elsewhere (5). Briefly, the ARPEC study group was a collabora-
tive partnership between members of the European Surveillance of Anti-
microbial Consumption, European Society of Pediatric Infectious Dis-
eases, and Global Research in Pediatrics networks. Hospital-based
physicians caring for neonates or children within these networks were
invited to participate. The departments within the participating centers
recorded data between October and December 2012. All inpatients 18
years of age present at 8 a.m. on the day of survey were included in the
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denominator. Data were recorded for patients who were prescribed anti-
microbial agents on the day of the survey.Neonates and children receiving
antifungal agents known to have negligible bioavailability administered
via the oral route (amphotericin B, nystatin, and miconazole) were ex-
cluded from analysis. The patient exclusion criteria included emergency
admission on the day of study, patients on psychiatric wards, and patients
18 years old admitted to an adult ward.
Anonymized patient data were collected through a study-specific on-
line portal using a standardized data entry protocol. The project focused
on European centers. In addition, centers outside Europe that collected
and submitted data according to the same methodology during the study
periods were included in the analysis. The data collected for all patients
receiving antimicrobials included age, gender, current weight and birth-
weight, ventilation status, and the prescribed antimicrobial agents, single
unit dose, number of doses per 24 h, route of administration, and drug
indication (therapeutic or prophylaxis). To facilitate data collection on
the underlying diagnosis and reason for treatment, a predefined list of
grouped underlying conditions, acute diagnoses, and anatomical site of
infection was used and is described elsewhere (5). The individual center
and department type were recorded categorically. Neonates were defined
based on postmenstrual age at the time of participation. The classification
of the level of neonatal care was defined locally, according to previously
described predetermined categories (7).Where dose frequencies were less
than daily and an antifungal agent was consequently prescribed but not
administered on the day of study, patients were included and doses deci-
malized to account for the frequency of administration.
Descriptive statistical analysis was carried out using Stata 10 and R
(version 2.15.3) (8, 9). An analysis of antifungal dosing was performed
using the total daily dose in 24 h (TDD). The TDDs were analyzed per
unit of current weight or estimated surface area (kg or m2), according to
the current guidance for each drug (Table 1). The following Anatomical
Therapeutic Chemical classes (version 2011) were analyzed: antimycotics
(ATC J02), antifungals for systemic use (ATC D01B), and intestinal anti-
infectives (ATC A07) (10). The dosing regimens were analyzed by nation
and macrogeographical regions using the United Nations geoscheme
(11).
The mean and variance of the TDDs for each antifungal agent were
compared to currently recommended regimens. The recommended daily
doses (RDD) were defined using collated guidance from the summary of
product characteristics (SPC), the European Society of Pediatric Infec-
tiousDisease (ESPID), theManual of childhood infections: the blue book,
3rd ed. (12), and Red book 2012: 2012 report of the Committee on Infec-
tious Diseases (13).Where specific dosing recommendations for pediatric
or neonatal populations could be derived from the respective SPC, these
formed the basis of the total daily dose recommendations. The dosing
recommendations are summarized in Table 1.
The upper and lower limits for recommended TDD were identified
from the range produced from the collated dosing recommendations and
used to define the maximum recommended daily doses (MaxRDD) and
minimum recommended daily doses (MinRDD). Dosing errors were de-
fined as prescription of medication at a dose meeting one of the following
criteria: (i) TDD prescribed at110% of the MaxRDD, or (ii) TDD pre-
scribed at 90% of the MinRDD. For example, the MinRDD and
MaxRDD for voriconazole in children age 2 to 12 years were determined
as follows: the highest current recommended dosing regimen (excluding
loading doses) was 8 mg/kg of body weight every 12 h, and the lowest
dosing regimen was 4 mg/kg every 12 h (see Table 1) during the study
period (14–22). TheMaxRDD andMinRDDwere therefore calculated to
be 16mg/kg and 8mg/kg daily, respectively, and the supra- and subthera-
peutic doses were calculated to be17.6 mg/kg and7.2 mg/kg, respec-
tively. The doses were defined according to age categories and route of
administration (where specified in the guidelines). A full description of
this methodology is described in detail elsewhere (23). Doses exceeding
values 10-fold above theMaxRDDor below theMinRDDwere considered
isolated prescribing or data entry errors and were excluded from analysis.
In accordance with European regulations, the anonymized data ob-
tained during this observational study were gathered without additional
therapy, monitoring procedures, or a change from existing clinical prac-
tices. Submission to the institutional review boards of participating cen-
ters was at the discretion of individual lead investigators.
RESULTS
Patient demographics.Data were recorded from 17,693 neonatal
and pediatric inpatients from 226 centers. The participating cen-
ters were from 19 European countries and 17 countries outside
Europe (see Table 2). A total of 1,345 inpatients from 136 centers
were prescribed at least one oral or parenteral antifungal. This
included 203 neonates and 379 children receiving antifungal
agents known to have negligible bioavailability administered via
the oral route (amphotericin B, nystatin, and miconazole) and
were therefore excluded. The data from five patients were ex-
cluded due to errors in data entry. In total, 885 patients were
evaluable (Fig. 1), with 174 neonates and 711 children (1month to
18 years old). Themedian ages of the neonates and children in the
study were 13 days (interquartile range [IQR], 7 to 19 days) and
6.5 years (IQR, 1 to 13 years), respectively.
Antifungal use. The most commonly prescribed agent for ne-
onates and children during the study was fluconazole, accounting
for 355 (40%) prescriptions (see Fig. 2). Second-generation tria-
zoles were less commonly prescribed (voriconazole, n  87
[10%]; posaconazole, n 14 [2%]). Fifty children (6%) received
oral itraconazole. Amphotericin B deoxycholate was the second
most frequently prescribed drug. Of 262 patients prescribed am-
photericin B, 197 (75%) were prescribed amphotericin B deoxy-
cholate (DAmB). The majority of the DAmB prescriptions (n 
150 [76%]) were from European centers. Lipid amphotericin B
preparations (liposomal, lipid complex, and colloid dispersion)
were prescribed less frequently than was conventional amphoter-
icin B (n 65 [8%]), of which 51 prescriptions (78%)were within
European centers. The use of echinocandins was less common
than that of amphotericin B formulations and azoles (caspofun-
gin, n 55 [6%]; micafungin, n 32 [4%]). One child received
parenteral flucytosine for the treatment of a catheter-related
bloodstream infection. Forty-two patients received combination
antifungal therapy. The most commonly prescribed drug combi-
nations used were amphotericin B-fluconazole (n  7), ampho-
tericin B-caspofungin (n  6), and caspofungin-voriconazole
(n 6).
Indication. Systemic antifungal treatment was reported in 174
neonates. Extremely low-birthweight neonates accounted for the
majority of antifungal prescriptions (n  103 [60%]). The most
common indications for systemic antifungal treatment in neo-
natesweremedical prophylaxis in 80 cases (46%) and treatment of
suspected IFI in 77 cases (44%). The treatment of localized infec-
tion was uncommonly reported (cardiac infection, n 2; central
nervous system [CNS] infection, n 4; genitourinary tract infec-
tion, n 3; lower respiratory tract infection, n 2; other/infective
source unknown, n  4). An ANOVA demonstrated no signifi-
cant effect of clinical indication (prophylaxis or treatment of sys-
temic or localized infection) on TDD (F 1.1, P 0.342).
Themost common indication for antifungal administration in
children was medical prophylaxis (n  325 [46%]), followed by
empirical treatment of febrile neutropenia (n  122 [17%]) and
treatment of confirmed or suspected IFI (n  100 [14%]). Anti-
fungal treatment of a localized infection was less commonly re-
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ported (respiratory tract, n  41; skin and soft tissue, n  15;
urinary tract, n  14; gastrointestinal, n  12; CNS, n  4; joint
and bone, n  4; cardiac, n  4). In 70 cases, the indication for
treatment was not known or recorded.
Route of administration. Systemic antifungals were adminis-
tered via the oral route in 58% and the parenteral route in 42% of
children. The majority of prescriptions in neonates were admin-
istered via the parenteral route (n 154 [89%]). Twenty neonates
received oral fluconazole. In children, oral administration ac-
counted for 108/254 (43%) of the fluconazole prescriptions and
50/87 (57%) of the voriconazole prescriptions. ThemeanTDD for
children receiving fluconazole via the oral route was significantly
lower (X  1.8mg1 kg1 day; standard deviation [SD], 8.3) than
that via the intravenous route (X  3.5 mg1 kg1 day; SD, 6.2;
TABLE 1 Currently published systemic antifungal dosing recommendations for neonates and children
Drug (dose units)a and patient category
Summary of product
characteristics
Manual of childhood infections: the blue
book, 3rd ed (12)
Red book 2012: 2012 report of the
Committee on Infectious Diseases (13)
Amphotericin B lipid complex (mg/kg)
Neonatal No recommendation No recommendation No recommendation
Pediatric 5 daily 5 daily 5 daily
Liposomal amphotericin B (mg/kg)
Neonatal No recommendation 3–5 daily No recommendation
Pediatric 1–3 daily 3–5 daily 3–5 daily
Amphotericin B deoxycholate (mg/kg)
Neonatal No recommendation 1 daily No recommendation
Pediatric 1 daily 1–1.5 daily 1–1.5 daily
Caspofungin (mg/m2)
Neonatal 25 daily 25 daily No recommendation
Pediatric 50 daily 1–3 mo, 25 daily; 3–12 mo, 50 daily; 1–18
yr, 70 daily
70 daily
Fluconazole (mg/kg)
Neonatal 0–14 days, 3–12 every 72 h;
15–17 days, 3–12 every 48 h
12 daily No recommendation
Pediatric Treatment, 6–12 daily;
prophylaxis, 3–12 daily
12 daily (max, 400 mg daily)b 6–12 daily
Itraconazole (mg/kg)
Neonatal No recommendation No recommendation No recommendation
Pediatric 5 daily Intravenous, 2.5 every 12 h for first 2
doses and then 2.5 daily; oral, 3–5 daily
(max, 200 mg daily)
5–10 daily
Micafungin (mg/kg)
Neonatal Treatment, 2–4 daily;
prophylaxis, 1 daily
Treatment, 8 daily; prophylaxis, 1 daily No recommendation
Pediatric (mg/kg) Body wt40 kg: treatment,
2–4 daily; prophylaxis, 1
daily; body wt40 kg:
treatment, 100–200 mg
daily; prophylaxis, 50 mg
daily
Treatment, 2–8 daily (max, 100 mg daily);
prophylaxis, 1 daily (max, 50 mg daily)
4–12 daily
Posaconazole
Neonatal No recommendation No recommendation No recommendation
Pediatric No recommendation 12 yr, 800 mg per day No recommendation
Voriconazole (mg/kg)
Neonatal No recommendation No recommendation No recommendation
Pediatric Intravenous load, 9 every 12 h
for first 2 doses and then 8
every 12 h; oral, 9 every 12
h (max, 700 mg daily)
Intravenous: 2–12 yr, 4–7 every 12 h; 2–12
yr, 4–7 every 12 h; 12–18 yr, 6 every 12
h for first 2 doses and then 3–4 mg
every 12 h; oral: 10 daily (max, 400 mg)
every 12 h for first 2 doses and then 7
every 12 h (max, 200 mg daily)
Intravenous: 2–12 yr, 9 every 12 h
(max, 700 mg daily); 12–18 yr, 6
every 12 h for first 2 doses and then
4 every 12 h; oral: 9 every 12 h
a The doses given for each drug are in the units in parentheses, unless otherwise specified.
b max, maximum.
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P0.001). Similarly, themean TDD for children receiving oral
voriconazole was lower (X  6.1 mg1 kg1 day; SD, 4.9) than
that for intravenous voriconazole (X  7.3 mg1 kg1 day; SD,
5.8; P 0.257).
Dosing. The proportions of patients receiving doses outside
the MinRDD andMaxRDD for each antifungal agent in neonates
and children are shown in Fig. 2. Overall, fewer than one-half of
the patients (n  371 [42%]) received a TDD within the dosing
range recommended in current guidelines. Subtherapeutic doses
(90% of the MinRDD) were prescribed in 416 cases (47%). The
most commonly prescribed drug, fluconazole, was prescribed at
subtherapeutic doses in 242/384 (63%) cases (Fig. 3). Amphoter-
icin B deoxycholate was prescribed at a subtherapeutic TDD in
83/200 (42%) cases. Two neonates received amphotericin B lipid
complex at a dose of 5 mg1 kg1 day. Recently, the efficacy and
population pharmacokinetics of amphotericin B lipid complex
(ABLC) have been described in neonates, and a dose of 2.5 to 5
mg1 kg1 day was incorporated into European guidelines for the
treatment of invasive candidiasis (24).
Center and department categories. The majority of neonatal
antifungal prescriptions occurred in tertiary (level III) neonatal
units (n  146 [84%]). For the pediatric population, antifungals
were prescribed most frequently in hematology-oncology wards
(n  352 [50%]) and pediatric intensive care units (n  121
[17%]). Less frequently, antifungal prescriptions were recorded in
surgical transplant units (n  75), general pediatric wards (n 
73), surgical wards (n  32), cardiac wards (n  16), and other
specialist pediatric wards (n 42).
The TDDs for children receiving therapeutic dosing regimens
of fluconazole varied substantially between centers and by depart-
ment type; these are shown in Fig. 3. The mean TDDs were signif-
icantly lower in general pediatric wards (n  18; X  3.9 mg1
kg1 day; SD, 4.9), hematology-oncology units (n 50; X  3.6
mg1 kg1 day; SD, 5.4), and surgical transplant units (n  12;
X  6.1 mg1 kg1 day; SD, 3.7) than that in the pediatric inten-
sive care unit (PICU) (n 28; X  7.1 mg1 kg1 day; SD, 3.3),
cardiac wards (n  5; X  6.1 mg1 kg1 day; SD, 7.9), and
surgical units (n 15; X  6.3mg1 kg1 day; SD, 7.5; P 0.001)
(Fig. 3). Themean therapeutic fluconazole TDDswere low in both
level III (n  67; X  2.2 mg1 kg1 day; SD, 6.3) and level I/II
units (n 6; X  3.5 mg1 kg1 day; SD, 3.9).
Amphotericin B was most frequently prescribed on hematology-
oncology units and in the PICU. Overall, amphotericin B deoxy-
cholate (DAmB) was prescribed more frequently than lipid
formulations of amphotericin B (liposomal amphotericin B
[LAmB]), accounting for 200 and 62 prescriptions, respectively.
ThemeanTDDs for therapeutic amphotericin Bwere significantly
lower in general pediatric wards (n 14; X  0.6 mg1 kg1 day;
SD, 2.0), hematology-oncology units (n 78; X  0.7 mg1 kg1
day; SD, 2.8), and level I/II neonatal units (forDAmB, n 10; X 
0.4 mg1 kg1 day; SD, 3.2) than those in the PICU (for DAmB,
n 27; X  1.3 mg1 kg1 day; SD, 4.1), level III neonatal units
(for DAmB, n  20; X  1.2 mg1 kg1 day; SD, 0.8), surgical
transplant units (for DAmB, n 14; X  1.1 mg1 kg1 day; SD,
TABLE 2 Number of children and neonates from participating centers
by country
Location
No. of centers
(n 136)
No. of pediatric
patients (n 711)
No. of neonatal
patients (n 174)
Western Europe
Belgium 6 27 1
France 6 75 19
Germany 15 96 16
Netherlands 1 10
Switzerland 1 19
Northern Europe
Estonia 1 7 4
Latvia 2 14 1
Lithuania 1 1
United Kingdom 37 94 33
Eastern Europe
Hungary 1 8
Romania 1 9
Southern Europe
Croatia 2 9
Greece 5 35 9
Italy 6 67 17
Malta 1 2
Portugal 3 12 1
Slovenia 1 8
Spain 6 42 16
Asia
Bahrain 1 3 1
India 7 29 21
Iran 3 15 1
Kuwait 2 3 3
Saudi Arabia 3 16 6
Oman 1 6
Oceania
Australia 6 53 2
Africa
Gambia 2 1
Ghana 1 1
Malawi 2 3
South Africa 1 3 7
Latin America
Argentina 1 21 2
Colombia 3 3 2
Mexico 1 25 3
North America
USA 3 64 4
FIG 1 Study flowchart and reasons for patient data eligibility/exclusion.
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0.7), and other specialty medical wards (for DAmB, n 11; X 
1.2 mg1 kg1 day; SD, 2.0; P 0.001).
DISCUSSION
This prospective observational study has provided a detailed de-
scription of the current prescribing practices of systemic antifun-
gals for hospitalized neonates and children. Significant underdos-
ingwithin the participating centers was identified, with fewer than
one-half of the recorded prescriptions delivering a daily dose
within the ranges recommended in current international guide-
lines and SPCs. The lowest mean daily therapeutic doses were
reported in general pediatric and hematology-oncology units. The
dosing varied across countries and regions, but no specific rela-
tionship was found between geographical distribution and the
proportion of patients receiving subtherapeutic doses. A similar
striking variability in dosing has been identified in the treatment
of invasive fungal infections in pediatric cancer patients (25). Re-
cent observational studies have also identified that suboptimal
dosing of antibacterial and antiviral drugs in children is similarly
prevalent. Saxena et al. (26), reporting prescribing surveillance
data from the United Kingdom, identified that children and ado-
lescents prescribed oral penicillin received doses below the na-
tional recommendations in 40% and 70% of cases, respectively.
Menson et al. (27) described the widespread suboptimal dosing of
antiretroviral drugs in children and identified several potential
causes of error, including the inadequacy of pharmacokinetic-
pharmacodynamic (PK-PD) data. Evidence-based dosing recom-
mendations for the older and more commonly prescribed anti-
fungal agents in this study are extremely limited for neonates and
children. Optimal doses have never been specifically defined for
fluconazole and amphotericin B deoxycholate in pediatric popu-
lations, despite their widespread use. Many of the more recently
introduced antifungal agents, such as echinocandins and second-
generation triazoles, have been specifically studied and differen-
tially licensed for use in neonates and children (28–31). Well-
designed prospective PK-PD studies in clinical settings, in
conjunction with modeling and simulation based on preclinical
data, are the best tools for establishing equivalent evidence-based
optimal dosing regimens for these older agents (32).
As in previous observational studies, systemic antifungals were
most frequently prescribed for the prevention and treatment of
IFI in immunosuppressed children and preterm neonates (33–
35). Indication-specific dosingwas recently described for flucona-
zole use in neonates. In the treatment of suspected or confirmed
IFI in neonates, a minimum daily dose of fluconazole of 12 mg1
kg1 day in the first 90 days of life results in comparable exposure
to adults receiving 800 mg daily and achieves an area under the
concentration-time curve (AUC)/MIC ratio of 50 (36). This
study observed a large proportion of patients receiving prophylac-
tic treatment and no significant differences between the mean
daily doses of fluconazole prescribed for prophylaxis versus ther-
apeutic use. This suggests a lack of awareness of indication-spe-
cific dosing in clinical practice and may reflect the difficulties as-
sociated with diagnosing IFI in children.
In conjunction with an improved evidence base to underpin
antifungal dosing, a global consensus between key organizations
issuing dosing recommendations (including those representing
specialized high-risk populations) is needed for the treatment and
prevention of IFI in pediatrics. An excellent example of such a
consensus is the unification of pediatric antiretroviral guidelines
published by the WHO, CDC, and Pediatric European Network
for Treatment of AIDS (PENTA), which have resulted in consol-
FIG 2 Numbers of patients receiving individual antifungal agents. For each drug, the left bar is pediatric patients and the right bar is neonates. Supratherapeutic
(TDD,110%of publishedMaxRDD), therapeutic, and subtherapeutic (TDD,90%of publishedMinRDD) doses are represented in dark gray, light gray, and
black, respectively. DAmB, amphotericin B deoxycholate; LAmB, liposomal amphotericin B; ABLC, amphotericin B lipid complex.
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idated international guidelines for the treatment of HIV (37, 38).
The harmonization of existing international pediatric antifungal
guidelines (for example, the European Conference on Infections
in Leukaemia [ECIL] and the European Society of ClinicalMicro-
biology and Infectious Diseases [ESCMID]) should similarly aim
to select pragmatic dosing and monitoring schedules while ac-
counting for differences in PK across children and neonates of
different sizes and developmental stages (25, 39).
Antimicrobial stewardship programs (ASP) have been shown
to increase appropriate antimicrobial prescribing practices, im-
prove individual patient outcomes, and reduce health care costs
(40). Recently, ASPs incorporating antifungal stewardship have
beendescribed in adults. These programshave identified key com-
ponents of antifungal stewardship, which include (i) the utiliza-
tion of appropriate antifungal drugs, including consideration and
monitoring of local resistance patterns, (ii) appropriate antifungal
doses based on published guidelines, with considerations of pa-
tient-specific PK-PD, (iii) clinical considerations, including the
removal of intravenous catheters, adequate diagnostics (serial
blood culture, antigen testing, and imaging techniques), and the
performance of examinations to investigate disseminated disease,
and (iv) a clear distinction between prophylactic and therapeutic
antifungal use, with appropriate use and duration of therapy
based on explicit clinical criteria in these settings (41–44).
Antibacterial ASPs in pediatric centers worldwide have re-
cently been reported (45–47). However, as in the adult popula-
tion, the relative infrequency of antifungal use compared with the
use of antibacterial drugs has led to the development of antifungal
stewardship being less forthcoming. The integration of antifungal
stewardship within existing ASPs that currently focus predomi-
nantly on antibacterial use seems to be a pragmatic way forward to
stimulate and improve appropriate antifungal prescribing prac-
tices.
PPS studies provide a large volume of information from awide
range of clinical settings at one time, and the participation rates in
this study were excellent compared with those in equivalent stud-
ies. A great strength of such a PPS study is the opportunity to
collect data on dosing and specific indications without relying on
subjective questionnaire-based studies. The opportunistic sam-
pling technique does, however, mean that the prescribing prac-
tices reported in this study may not be representative of centers
and/or countries that did not take part. Additionally, dosing epi-
sodes for rare indications or of antifungal agents that are infre-
quently prescribed may be omitted on the day of study. Further
systematic observational studies should aim to increase the num-
ber of participating centers in a variety of global settings (includ-
ing high- and low-income countries) in order to further describe
geographical variations, center-specific outcomes, and patient-re-
lated trends in antimicrobial use. A significant proportion of cen-
ters reported therapeutic antifungal use. Further data about
infective organism and resistance patterns will yield important
information to guide antifungal stewardship programs. Further-
more, this study did not gather qualitative information, such as
clinician rationale (for example, a consideration of renal and/or
hepatic impairment) and team member involvement in clinical
decisions regarding drug and dose selection. Repeated and/or lon-
gitudinal surveys within participating institutions may gather
such data and identify prescribing trends over time.
Overall, variability in antifungal prescriptions and widespread
systematic suboptimal prescription of antifungals appears to be
significant problems in neonates and children. Well-designed
clinical studies in conjunction with PK modeling and simulation
to inform guidelines, as well as the incorporation of antifungal
FIG 3 Total daily dosing of fluconazole prescribed as treatment for invasive fun-
gal infection in pediatric patients by macrogeographical regions (A) and center
type (B). Interquartile range (IQR), median, 1.5 the IQR, and outlying data
points are represented by boxes, central lines, whiskers, and open circles, respec-
tively. The minimum and maximum recommended daily doses are indicated by
the dashed lines.
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stewardship into current and future ASPs, are urgently needed to
improve prescribing practices and clinical outcomes.
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